Skip to main content
Equibles

4536 · SANTEN PHARMACEUTICAL CO.,LTD. · Financials

Use 4536 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4536.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,017.5 JPY -3 (-0.15%) At close · Nov 10
Rebalance outlook locked
Market Cap
648.19B JPY
Shares
321.28M
Volume · Nov 10 1.57M Avg daily vol (3M) 1.3M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
291.62B -2.8%
FY2026 Revenue FY2022–FY2026
Net Income
37.37B +3.1%
FY2026 Net Income FY2022–FY2026
Gross Margin
58.21% +1.2pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
16.39% +0.8pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
43.5B -28.6%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 291.62B 300B 301.97B 279.04B 266.26B
JPY 121.88B 128.98B 123.26B 112.95B 109.67B
JPY 169.74B 171.03B 178.71B 166.09B 156.59B
JPY 47.8B 46.88B 38.54B -3.09B 35.89B
JPY 47.44B 47.48B 29.87B -5.8B 35.62B
JPY 9.88B 11.63B 3.17B 9.18B 8.43B
JPY 37.37B 36.26B 26.64B -14.95B 27.22B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 61.24B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.